Business
Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":"NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced the following presentations at the upcoming 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Meeting, which will be held June 11-14, 2022 in Vancouver, BC, Canada. Presentation details are as follows: PYLARIFY® (Piflufolastat F18), PSMA-targeted PET imaging agent for prostate cancerOral Presentation:Date & Time: June 14, 2022, 3:00 – 4:30 PM PTSession Title: Urologic MalignanciesTitle: The Impact of Concomitant Use of Androgen Deprivation Therapies (ADT) on the Efficacy of Piflufolastat F 18-PET/CT in Patients with Prostate Cancer: a Sub-group Analysis of OSPREY Cohort BPresenter: Lawrence Saperstein, MD, Associate Professor of Clinical Radiology and Biomedical Imaging; Chief, Nuclear Medicine, Yale School of MedicinePublication (Program ID): 2625 PYLARIFY AI™, FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scansOral Presentation: Date & Time: June 12, 2022, 3:00 – 4:30 PM PTSession Title: Oncology Basic/Translational Integrated SessionTitle: Prospectively planned and Independent Validation of aPROMISE in a Phase III CONDOR Study for Rapid Lesion Detection and Standardized Quantitative Evaluation for 18F-DCFPyL (PSMA) Imaging in Prostate Cancer*Presenter: Jeremie Calais, MD, MSc, Assistant Professor, Department of Molecular and Medical Pharmacology, Director, UCLA Theranostics Program, Ahmanson Translational Theranostics Division, University of California, Los AngelesPublication (Program ID): 2496*nominated for the Henry N. Wagner, Jr., MD “Image of the Year” Poster Presentation: Title: Quantitative Assessment of PSMA PET Response to Androgen Deprivation in Veterans with Treatment Naïve Castration Sensitive Prostate Cancer Presenter: Nicholas G. Nickols, MD, PhD, Associate Professor in Radiation Oncology at UCLAPublication (Program ID): 3070 Tc99m-NM-01, novel imaging agent currently under development for the assessment of PD-L1 expression in non-small cell lung cancerOral Presentation: Date & Time: June 12, 2022, 12:30 – 2...